Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PDUFA Acronym War Begins: Could Reauthorization Be Called Patient-UFA?

Executive Summary

For first time ever, the administration that negotiated a user fee agreement won’t be shepherding its reauthorization through Congress.


Related Content

PDUFA VI: Industry Ready For 'Hard Sell' To Keep Agreement Intact
21st Century Cures Revisions Tell FDA To Highlight ‘Patient Experience Data’
False Claims, Enforcement Changes Possible Under Trump Administration
PDUFA First: Fees To Support Device Center Staff
You Just Have To Wait: FDA Can't Hurry PDUFA VI Guidances
Patient-Focused Drug Development At 10: Where Does It Go From Here?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts